Abstract
In silico and in vitro methods have emerged as valuable tools to rapidly screen and prioritize large numbers of chemicals including new drug entities, food ingredients, and environmental compounds for further in vivo analysis. These methods have been frequently used to conduct screening for a wide range of endpoints including physicochemical properties (e.g., logD), human biokinetic parameters (e.g., metabolism), and human organ toxicities (e.g., hepatotoxicity). This chapter describes a tiered approach of incorporating multiple in silico (quantitative structure–activity relationship, QSAR) and in vitro (e.g., human liver cell models, human liver microsomes) methods into the screening of hepatotoxic chemicals and cytochromes P450 enzyme (CYP) inhibitors. Chemicals are prioritized for further studies (e.g., in vivo animal study) based on the in silico and in vitro results, as well as a literature search for their in vivo exposures (e.g., plasma concentration).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fisher K, Vuppalanchi R, Saxena R (2015) Drug-induced liver injury. Arch Pathol Lab Med 139(7):876–887. https://doi.org/10.5858/arpa.2014-0214-RA
Katarey D, Verma S (2016) Drug-induced liver injury. Clin Med (Lond) 16(Suppl 6):s104–s109. https://doi.org/10.7861/clinmedicine.16-6-s104
Docea AO, Vassilopoulou L, Fragou D, Arsene AL, Fenga C, Kovatsi L, Petrakis D, Rakitskii VN, Nosyrev AE, Izotov BN, Golokhvast KS, Zakharenko AM, Vakis A, Tsitsimpikou C, Drakoulis N (2017) CYP polymorphisms and pathological conditions related to chronic exposure to organochlorine pesticides. Toxicol Rep 4:335–341. https://doi.org/10.1016/j.toxrep.2017.05.007
Manikandan P, Nagini S (2018) Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 19(1):38–54. https://doi.org/10.2174/1389450118666170125144557
Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y (2008) Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 83(1):61–69. https://doi.org/10.1038/sj.clpt.6100222
Fraczkiewicz R, Lobell M, Goller AH, Krenz U, Schoenneis R, Clark RD, Hillisch A (2015) Best of both worlds: combining pharma data and state of the art modeling technology to improve in silico pKa prediction. J Chem Inf Model 55(2):389–397. https://doi.org/10.1021/ci500585w
Liu Y (2018) Incorporation of absorption and metabolism into liver toxicity prediction for phytochemicals: a tiered in silico QSAR approach. Food Chem Toxicol 118:409–415. https://doi.org/10.1016/j.fct.2018.05.039
Wetmore BA (2015) Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. Toxicology 332:94–101. https://doi.org/10.1016/j.tox.2014.05.012
Blaauboer BJ (2010) Biokinetic modeling and in vitro-in vivo extrapolations. J Toxicol Environ Health B Crit Rev 13(2–4):242–252. https://doi.org/10.1080/10937404.2010.483940
Liu Y, Mapa MST, Sprando RL (2020) Liver toxicity of anthraquinones: a combined in vitro cytotoxicity and in silico reverse dosimetry evaluation. Food Chem Toxicol 140:111313. https://doi.org/10.1016/j.fct.2020.111313
Saeheng T, Na-Bangchang K, Karbwang J (2018) Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review. Eur J Clin Pharmacol 74(11):1365–1376. https://doi.org/10.1007/s00228-018-2513-6
Liu Y, Mapa MST, Sprando RL (2021) Anthraquinones inhibit cytochromes P450 enzyme activity in silico and in vitro. J Appl Toxicol 41(9):1438–1445. https://doi.org/10.1002/jat.4134
Ghosh J, Lawless MS, Waldman M, Gombar V, Fraczkiewicz R (2016) Modeling ADMET. Methods Mol Biol 1425:63–83. https://doi.org/10.1007/978-1-4939-3609-0_4
Agrawal S, Dhiman RK, Limdi JK (2016) Evaluation of abnormal liver function tests. Postgrad Med J 92(1086):223–234. https://doi.org/10.1136/postgradmedj-2015-133715
Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007
Jana S, Rastogi H (2017) Effects of Caffeic acid and quercetin on in vitro permeability, metabolism and in vivo pharmacokinetics of melatonin in rats: potential for herb-drug interaction. Eur J Drug Metab Pharmacokinet 42(5):781–791. https://doi.org/10.1007/s13318-016-0393-7
Nehlig A (2018) Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev 70(2):384–411. https://doi.org/10.1124/pr.117.014407
Tornio A, Backman JT (2018) Cytochrome P450 in pharmacogenetics: an update. Adv Pharmacol 83:3–32. https://doi.org/10.1016/bs.apha.2018.04.007
U.S. Food and Drug Administration (2016) Drug development and drug interactions: table of substrates, inhibitors and inducers. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table1
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply
About this protocol
Cite this protocol
Liu, Y. (2022). Use In Silico and In Vitro Methods to Screen Hepatotoxic Chemicals and CYP450 Enzyme Inhibitors. In: Zhu, H., Xia, M. (eds) High-Throughput Screening Assays in Toxicology. Methods in Molecular Biology, vol 2474. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2213-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2213-1_17
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2212-4
Online ISBN: 978-1-0716-2213-1
eBook Packages: Springer Protocols